1220701-48-3Relevant academic research and scientific papers
Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient
-
Page/Page column 19, (2016/08/17)
The present invention relates to a novel imidazole-1-yl pyrimidine derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutic composition comprising the same. Since the imidazole-1-yl pyrimidine derivative according to the present inventio
Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors
Kim, Minjung,Lee, Junghun,Jung, Kyungjin,Kim, Hyangmi,Aman, Waqar,Ryu, Jae-Sang,Hah, Jung-Mi
, p. 3600 - 3604 (2014/07/22)
The synthesis of a novel series of (4-aminobenzyl/benzoyl)-1H-imidazol-1-yl pyrimidin-2-yl derivatives 9, 10, 18, 19 and their in vitro antiproliferative activities against the A375P human melanoma cell line and the U937 human leukemic monocyte lymphoma cell line are described. Potent antiproliferative effects were found from 9l, 9s and 10c; 10c was found to be a highly potent and selective BRAF V600E and CRAF inhibitor (IC50 = 38.3 nM and 8.79 nM).
IMIDAZOLE DERIVATIVES AND COMPOSITIONS FOR TREATING MELANOMA
-
Page/Page column 32; 33, (2011/05/06)
The present invention relates to novel imidazole derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof and pharmaceutical compositions for prevention and treatment of melanoma containing the same as active ingredients. The
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines
Lee, Junghun,Kim, Hwan,Yu, Hana,Chung, Jae Yoon,Oh, Chang-Hyun,Yoo, Kyung Ho,Sim, Taebo,Hah, Jung-Mi
scheme or table, p. 1573 - 1577 (2010/06/20)
The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 μM, respectively) and turned out to be a selective and potent CRAF inhibitor.
